Universidade de Caxias do Sul, Caxias do Sul, RS, Brazil.
Arch Virol. 2024 Feb 20;169(3):52. doi: 10.1007/s00705-024-05995-8.
Parvoviruses are responsible for multiple diseases, and there is a critical need for effective antiviral therapies. Specific antiviral treatments for parvovirus infections are currently lacking, and the available options are mostly supportive and symptomatic. In recent years, significant research efforts have been directed toward understanding the molecular mechanisms of parvovirus replication and identifying potential targets for antiviral interventions. This review highlights the structure, pathogenesis, and treatment options for major viruses of the subfamily Parvovirinae, such as parvovirus B19 (B19V), canine parvovirus type 2 (CPV-2), and porcine parvovirus (PPV) and also describes different approaches in the development of antiviral alternatives against parvovirus, including drug repurposing, serendipity, and computational tools (molecular docking and artificial intelligence) in drug discovery. These advances greatly increase the likelihood of discoveries that will lead to potent antiviral strategies against different parvovirus infections.
细小病毒可引起多种疾病,因此急需有效的抗病毒疗法。目前针对细小病毒感染尚缺乏特效抗病毒药物,现有治疗方法主要为支持和对症治疗。近年来,大量研究致力于了解细小病毒复制的分子机制,并确定抗病毒干预的潜在靶点。本综述重点介绍了细小病毒亚科细小病毒属的主要病毒(如细小病毒 B19(B19V)、犬细小病毒 2 型(CPV-2)和猪细小病毒(PPV))的结构、发病机制和治疗选择,并描述了针对细小病毒开发抗病毒药物的不同方法,包括药物再利用、偶然发现和药物发现中的计算工具(分子对接和人工智能)。这些进展极大地增加了发现针对不同细小病毒感染的有效抗病毒策略的可能性。